{"article_title": "Pricey, Volatile Biotech Stocks Losing Favor", "article_keywords": ["prices", "biotech", "wealth", "valuations", "trials", "tastes", "favor", "pricey", "volatile", "split", "technologywe", "losing", "stocks", "steep"], "article_url": "http://www.wsj.com/articles/SB10001424052702304799404579157361679327966", "article_text": "Disappointing clinical trials and steep prices are leading some advisers to split their bets on biotech stocks between funds focused on health care and technology.\n\n\"We like to invest in companies with innovative products, but at reasonable prices. Biotech has become too rich for our tastes,\" says Curt Gross, research director at FAI Wealth Management in Columbia, Md., with $325 million in assets.\n\nMarket valuations...", "article_metadata": {"article.template": "snippet", "article.created": "2013-10-25T13:40:00.000Z", "article.section": "Wealth Management Journal", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Some financial advisers say biotech stocks are no longer attractive following disappointing clinical trials and a run-up in prices. They say health care and technology are better bargains.", "creator": "@ColemanFunds", "image": {"src": "https://si.wsj.net/public/resources/images/BN-AD195_WAJ_10_G_20131024125113.jpg", "alt": "Pricey, Volatile Biotech Stocks Losing Favor", "identifier": "https://si.wsj.net/public/resources/images/BN-AD195_WAJ_10_D_20131024125113.jpg"}, "title": "Pricey, Volatile Biotech Stocks Losing Favor", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304799404579157361679327966&headline=Pricey%2C%20Volatile%20Biotech%20Stocks%20Losing%20Favor&weburl=http://www.wsj.com/articles/SB10001424052702304799404579157361679327966"}}, "page.site.product": "WSJ", "keywords": "iShares North American Tech-Software ETF,IGV,SPDR S&P Biotech ETF,XBI,Ariad Pharmaceuticals,ARIA,Celgene,CELG,Coronado Biosciences,CNDO,Amarin,AMRN,Gilead Sciences,GILD,Biogen Idec,BIIB,Bank of America,BAC,iShares Nasdaq Biotechnology ETF,IBB,new products,services,corporate,industrial news,official trials,tests,biotechnology,political,general news,financial planners,advisors,personal finance,sciences,technologies,content types,factiva filters,fc&e industry news filter,banking,trusts,funds,financial vehicles,unit trusts,mutual funds,financial investments,health care,life sciences,credit,exchange traded funds,financial services,investing,securities,private banking,wealth management", "news_keywords": "iShares North American Tech-Software ETF,IGV,SPDR S&P Biotech ETF,XBI,Ariad Pharmaceuticals,ARIA,Celgene,CELG,Coronado Biosciences,CNDO", "article.headline": "Pricey, Volatile Biotech Stocks Losing Favor", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-AD195_WAJ_10_E_20131024125113.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-AD195_WAJ_10_D_20131024125113.jpg"}}, "description": "Some financial advisers say biotech stocks are no longer attractive following disappointing clinical trials and a run-up in prices. They say health care and technology are better bargains.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304799404579157361679327966&headline=Pricey%2C%20Volatile%20Biotech%20Stocks%20Losing%20Favor&weburl=http://www.wsj.com/articles/SB10001424052702304799404579157361679327966", "user.type": "nonsubscriber", "article.page": "Wealth Management Journal", "page.content.format": "responsive", "article.summary": "Some financial advisers say biotech stocks are no longer attractive following disappointing clinical trials and a run-up in prices. They say health care and technology are better bargains.", "page.site": "wsj", "testkeys": "C", "article.published": "2013-10-25T13:40:00.000Z", "dj.asn": "i-6fe2", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "author": "https://www.facebook.com/murray.coleman.16", "embed_count": 1, "word_count": 833, "internal_link_count": 6, "image_count": 1}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Some financial advisers say biotech stocks are no longer attractive following disappointing clinical trials and a run-up in prices. They say health care and technology are better bargains.", "title": "Pricey, Volatile Biotech Stocks Losing Favor", "url": "http://www.wsj.com/articles/SB10001424052702304799404579157361679327966", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-AD195_WAJ_10_G_20131024125113.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Murray Coleman", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Pricey, Volatile Biotech Stocks Losing Favor", "article.type": "Wealth Management Journal", "article.id": "SB10001424052702304799404579157361679327966", "user.exp": "default", "article.updated": "2013-10-25T13:40:00.000Z"}, "article_summary": "Disappointing clinical trials and steep prices are leading some advisers to split their bets on biotech stocks between funds focused on health care and technology.\nBiotech has become too rich for our tastes,\" says Curt Gross, research director at FAI Wealth Management in Columbia, Md., with $325 million in assets.\n\"We like to invest in companies with innovative products, but at reasonable prices.\nMarket valuations..."}